Kevin Strange is a biomedical scientist and entrepreneur. His research focuses on cellular stress biology, has been funded for more than 35 years by the National Institutes of Health (NIH), Department of Defense, and private foundations and has been published in leading journals including Science, PNAS, Neuron, Cell, Journal of Cell Biology, Journal of General Physiology and Biophysical Journal. Kevin holds bachelor’s and master’s degrees from the University of California at Davis, a doctorate from the University of British Columbia and completed his postdoctoral training at the National Institutes of Health.
After a distinguished career as a biomedical scientist and leader at Harvard Medical School and Vanderbilt University School of Medicine, Kevin became the first president and full-time director of the MDI Biological Laboratory (MDIBL) in 2009. At MDIBL he established the Maine Center for Biomedical Innovation and the Davis Center for Regenerative Biology and Medicine, which received $25 million in NIH funding and was recognized as an NIH Center of Biomedical Research Excellence. Together with Davis Center faculty member, Dr. Voot Yin, Kevin developed a novel regenerative medicine drug development program that led to the discovery of a chemical compound, MSI-1436, that dramatically stimulates the regeneration and repair of multiple tissue types in diverse animal models.
In 2013, Kevin and Dr. Yin founded Novo Biosciences to advance MSI-1436 into human clinical trials. Kevin stepped down as president of MDIBL in July 2018 to focus on managing and growing Novo Biosciences. As CEO, he manages all aspects of company business including partnerships, fundraising and investor relations. Kevin and Dr. Yin have been awarded three U.S., European and Japanese patents for MSI-1436, have received direct to Phase 2 NIH SBIR funding to further develop the compound as a novel regenerative medicine and recently closed a partnership deal and $4 million private investment in Novo Biosciences.